Work for BioLineRx Ltd.?

Claim Your Profile

BioLineRx Ltd. Logo Image

BioLineRx Ltd.

Most Recent Annual Report

Upgrade your company profile to unlock all of your annual report content on AnnualReports.com

2019 Annual Report

BioLineRx Ltd.

BioLineRx Ltd. has reached its limit for free report views.

Upgrade your company profile to unlock all of your annual report content on AnnualReports.com

Archived Annual Reports

About BioLineRx Ltd.

11-50 Employees
Based in Modi’in, Israel

BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a late clinical-stage biopharmaceutical company focused on oncology. The Company's business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization. The Company's lead program, motixafortide (BL-8040), is a cancer therapy platform currently being evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA® and chemotherapy under a collaboration agreement with MSD. Motixafortide is also being evaluated in a Phase 2b study in consolidation AML and a Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation.

Ticker:
BLRX
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Biotechnology (See More Biotechnology Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol